Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the aggressive lipid-lowering initiation abates new cardiac events (ALLIANCE) study
Mullins C D, Rattinger G B, Kuznik A, Koren M J

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
19281915

DOI
10.1016/j.clinthera.2008.12.007

Indexing Status
Subject indexing assigned by NLM

MeSH
Atorvastatin Calcium; Cardiovascular Diseases /economics /epidemiology /prevention & control; Cost-Benefit Analysis; Drugs, Generic /economics; Heptanoic Acids /economics /therapeutic use; Hospitalization /economics /statistics & numerical data; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors /economics /therapeutic use; Hyperlipidemias /drug therapy; Models, Economic; Myocardial Revascularization /economics /statistics & numerical data; Pyrroles /economics /therapeutic use; Randomized Controlled Trials as Topic

AccessionNumber
22009101132

Date bibliographic record published
23/09/2009